Alpha 2.0
Login Register
» Articles » PMID: 16416174

The Incidence of Abdominal and Pelvic Surgery Among Patients with Irritable Bowel Syndrome

Overview
Journal Dig Dis Sci
Specialty Gastroenterology
Date 2006 Jan 18
PMID 16416174
Citations 16
Authors
J Alexander Cole
Jason M Yeaw
Jennifer A Cutone
Braden Kuo
Zhiping Huang
David L Earnest
Alexander M Walker
Affiliations
Soon will be listed here.
Abstract

Rates of abdominopelvic surgery, with a particular focus on gallbladder procedures, were measured in patients with irritable bowel syndrome (IBS) (n = 108,936) and compared with those in a general population sample (n = 223,082). The patient sample was selected from persons who were members of a managed care organization during the years 1995-2000. Medical records from a randomly selected subset of IBS patients were reviewed to confirm the diagnosis. Crude and standardized rates and adjusted rate ratios for surgery were calculated. The incidence of abdominopelvic surgery, excluding gallbladder procedures, was 87% higher in patients with IBS than that for the general population. The incidence of gallbladder surgery was threefold higher in IBS patients than the general population. Patients with IBS have an increased risk for abdominopelvic and gallbladder surgery and, thus, an associated risk for experiencing morbidity and mortality associated with these surgical procedures.

Citing Articles

Patients With Somatoform Disorders Are Prone to Expensive and Potentially Harmful Medical Procedures—Results of a Retrospective Cohort Study Over 15 Years.

Schneider A, Donnachie E, Zipfel S, Enck P Dtsch Arztebl Int. 2021; 118(25):425-431.

PMID: 34374332 PMC: 8381614. DOI: 10.3238/arztebl.m2021.0135.

Irritable bowel syndrome in midlife women: a narrative review.

Yang P, Heitkemper M, Kamp K Womens Midlife Health. 2021; 7(1):4.

PMID: 34059117 PMC: 8166071. DOI: 10.1186/s40695-021-00064-5.

Economic burden of moderate to severe irritable bowel syndrome with constipation in six European countries.

Tack J, Stanghellini V, Mearin F, Yiannakou Y, Layer P, Coffin B BMC Gastroenterol. 2019; 19(1):69.

PMID: 31064345 PMC: 6505116. DOI: 10.1186/s12876-019-0985-1.

'Do no harm': an intuitive decision tool to assess the need for gastrointestinal endoscopy.

Sonnenberg A, Pohl H Endosc Int Open. 2019; 7(3):E384-E388.

PMID: 30834299 PMC: 6395093. DOI: 10.1055/a-0826-4432.

Factors associated with more frequent diagnostic tests and procedures in patients with irritable bowel syndrome.

Lacy B, Ayyagari R, Guerin A, Lopez A, Shi S, Luo M Therap Adv Gastroenterol. 2019; 12:1756284818818326.

PMID: 30636972 PMC: 6317153. DOI: 10.1177/1756284818818326.

References
1.
Kellow J, Lee O, Chang F, Thongsawat S, Mazlam M, Yuen H . An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome. Gut. 2003; 52(5):671-6. PMC: 1773630. DOI: 10.1136/gut.52.5.671. View
2.
Talley N . Irritable bowel syndrome: definition, diagnosis and epidemiology. Baillieres Best Pract Res Clin Gastroenterol. 1999; 13(3):371-84. DOI: 10.1053/bega.1999.0033. View
3.
Muller-Lissner S, Fumagalli I, Bardhan K, Pace F, Pecher E, Nault B . Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther. 2001; 15(10):1655-66. DOI: 10.1046/j.1365-2036.2001.01094.x. View
4.
Novick J, Miner P, Krause R, Glebas K, Bliesath H, Ligozio G . A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Aliment Pharmacol Ther. 2002; 16(11):1877-88. DOI: 10.1046/j.1365-2036.2002.01372.x. View
5.
Horwitz B, Fisher R . The irritable bowel syndrome. N Engl J Med. 2001; 344(24):1846-50. DOI: 10.1056/NEJM200106143442407. View